When was CellType founded?

CellType was founded in 2025 and raised its 1st funding round 1 year after it was founded.

Where is CellType located?

CellType is headquartered in New York City, United States.

Who is the current CEO of CellType?

David Van Dijk of CellType. They have also founded 1 company.

How many employees does CellType have?

As of Apr 30, 2026, the latest employee count at CellType is 3.

Is CellType a funded company?

CellType is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jan 01, 2026.

When was the latest funding round of CellType?

CellType's latest funding was a $***** Seed round on Jan 01, 2026, with participation from 1 investor.

Where does CellType rank among its competitors?

CellType ranks 138th amongst 171 active competitors, of which 69 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Isomorphic Labs, which secured $2.1B in May, 2026.

Who are the top competitors of CellType?

CellType's top competitors include Schrodinger, Recursion Pharmaceuticals and XtalPi. Among them, Isomorphic Labs secured the most recent funding round in May, 2026.

CellType - 2026 Company Profile, Team, Funding & Competitors

CellType is a seed company based in New York City (United States), founded in 2025 by Ivan V and David Van Dijk. It operates as an AI-driven platform focused on drug discovery through biological simulation. CellType has raised $500K in funding. The company has 171 active competitors, including 69 funded and 12 that have exited. Its top competitors include companies like Schrodinger, Recursion Pharmaceuticals and XtalPi.

Company Details

AI-driven platform focused on drug discovery through biological simulation. The company utilizes artificial intelligence to simulate human biology and develop targeted drug therapies. The company leverages large datasets and machine learning algorithms to understand the patterns governing drug response and toxicity.

Website: www.celltype.com/
Social
Email ID: *****@celltype.com

Key Metrics

Founded Year

2025

Location

New York City, United States

Stage

Seed

Total Funding

$500K in 1 round

Latest Funding Round

Seed, Jan 01, 2026, $*****

Investors

Y Combinator

Ranked

138^th among 171 active competitors

Employee Count

3 as on Apr 30, 2026

Similar Companies

Schrodinger & 200 more

View CellType's full profile

CellType has raised a total funding of $500K over 1 round. Its latest funding round was a Seed round on Jan 01, 2026 for $*****. 1 investor participated in its latest round. CellType has 1 institutional investor.

Here is the list of recent funding rounds of CellType:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 01, 2026	7770698	Seed	2986312	5295113	9986339	2730142

Access funding benchmarks and valuations. Sign up today!

View details of CellType's funding rounds and investors

The founders of CellType are Ivan V and David Van Dijk. David Van Dijk is the CEO of CellType.

Here are the details of CellType's key team members:

Ivan V: Co-Founder of CellType.
David Van Dijk: Co-Founder & CEO of CellType.

View details of CellType's Founder profiles and Board Members

CellType's employee count trend

CellType has 3 employees as of Apr 26. Here is CellType's employee count trend over the years:

Uncover CellType's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CellType include Schrodinger, Recursion Pharmaceuticals and XtalPi. Here is the list of Top 10 competitors of CellType, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates, WuXi AppTec & 16 others	74/100
2nd	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, Felicis Ventures & 46 others	67/100
3rd	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	Orbimed, SoftBank Vision Fund & 25 others	67/100
4th	Isomorphic Labs 2021, London (United Kingdom), Series B	Digital platform focused on revolutionizing drug discovery using AI	$2.7B	Thrive Capital, Temasek & 5 others	64/100
5th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Arch Venture Partners, Foresite Labs & 11 others	63/100
6th	Causaly 2018, London (United Kingdom), Series B	Provider of an AI platform for life sciences and biomedical research	$93M	Index Ventures, Iconiq Capital & 14 others	63/100
7th	METiS Therapeutics 2017, Cambridge (United States), Series B	Provider of an AI-assisted platform for drug discovery and development	$252M	Sequoia Capital China, Luminous Ventures ... & 13 others	63/100
8th	Gero 2015, Singapore (Singapore), Series A	Developer of reverse engineering technology for controlling aging	$13.5M	Bulba Ventures, Melnichek Investments & 13 others	63/100
9th	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	63/100
10th	Tandem AI 2021, New York (United States), Series A	AI-based drug discovery tool for researchers	$82M	Orbimed, Qiming Venture Partners & 4 others	62/100
138th	CellType 2025, New York City (United States), Seed	AI-driven platform focused on drug discovery through biological simulation	$500K	Y Combinator	22/100